Actinium Pharma: Up as patient enrollment advances in cancer therapy study

Actinium Pharmaceuticals

25/03/2021 16:20

** Shares of cancer therapy developer  ATNM.A  rise 2.7% to
$8.52
    ** ATNM says it completed initial patient enrollment in a
portion of its early-stage trial testing second dose of its 
experimental therapy Actimab-A in combination with another drug 
for relapsed or refractory acute myeloid leukemia  urn:newsml:reuters.com:*:nPn2Dm5w1a
    ** Acute myeloid leukemia is a cancer of the blood and bone
marrow  
    ** Trial intended to determine maximum tolerable dose of
Actimab-A that is to be studied in the Phase 2 portion of co's
early-to-mid-stage study
    ** Co expects to complete early-stage trial and present
further proof-of-concept data in H2
    ** ATNM had presented data from the first dose group of the
trial at an industry meeting in December
    ** ATNM had gained 6.4% YTD, as of last close 

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))